VANCOMYCIN SUSCEPTIBILITY OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS ISOLATED FROM CLINICAL SPECIMENS AND ITS CLINICAL OUTCOME IN VANCOMYCIN TREATED PATIENTS ATTENDING A TERTIARY CARE HOSPITAL.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2015/08/006123

Enrollment

100

Registered

2015-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- 1. All MRSA isolates from clinical specimen like blood, respiratory samples, exudates, urine and body fluids.

Interventions

Control Intervention1: Sensitivity of tests different for detection of Vancomycin resistance: sensitivity of E- test and agar dilution to pick up vancomycin resistance

Eligibility

Inclusion criteria

Inclusion criteria: 1. All MRSA isolates from clinical specimen like blood, respiratory samples, exudates, urine and body fluids.

Exclusion criteria

Exclusion criteria: 1. Clinical specimens other than MRSA isolates. 2. MRSA isolates from nasal carriers.

Design outcomes

Primary

Measure	Time frame
1. To determine the occurrence of VISA and VRSA from the clinical MRSA samples.Timepoint: At the end of 1.5 years of collecting samples	—

Secondary

Measure	Time frame
To determine the minimum inhibitory concentration (MIC) of Vancomycin in MRSA isolates and to categories into VISA and VRSA strainsTimepoint: end of 1.5 years	—

Countries

India

Contacts

Public ContactDr Anup Kumar Shetty

Fr Muller Medical College

dranupshetty@gmail.com09900455220

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026